Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar;35(3):1024-1025.
doi: 10.1038/s41433-020-0982-1. Epub 2020 May 28.

Comment on "Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases"

Peter A Campochiaro  1 , Giulio Barteselli  2
Affiliations
Comment

Comment on "Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases"

Peter A Campochiaro et al. Eye (Lond). 2021 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

PAC: Advisory board—Aerpio, Allegro, Applied Genetic Technologies Corporation, Exonate, Genentech, Inc., Merck; Cofounder—Graybug Vision; Consultant—Alimera, Allergan, AsclepiX, Astellas, Graybug Vision, Intrexon, Novartis, RXI; Equity—Allegro, Graybug Vision; Honoraria—Applied Genetic Technologies Corporation, AsclepiX, Astellas, Exonate, Genentech, Inc., Graybug Vision, Intrexon, Merck, Novartis, RXI; Research support—Aerpio, Alimera, Allegro, Allergan, AsclepiX, Clearside, Genentech, Inc., Graybug Vision, Oxford Biomedica, Regeneron, Regenxbio, RXI, Sanofi Genzyme. GB: Employee—Genentech, Inc.; Stockholder—Genentech, Inc.

Comment in

Comment on

References

    1. Seah I, Zhao X, Lin Q, Liu Z, Su SZZ, Yuen YS, et al. Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. Eye. 2020; 10.1038/s41433-020-0770-y. - PMC - PubMed
    1. Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, et al. The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial. Ophthalmology. 2019;126:1141–54. doi: 10.1016/j.ophtha.2019.03.036. - DOI - PubMed
    1. Bantseev V, Schuetz C, Booler HS, Horvath J, Erickson S, Bentley E, et al. Evaluation of surgical factors affecting vitreous hemorrhage following Port Delivery System with ranibizumab implant insertion in a minipig model. Retina. 2019. 10.1097/IAE.0000000000002614. - PMC - PubMed